OncLive News Network On Location: ESMO 2020 Day 3

• Date :
• 3    
  0

ESMO 2020 Satellite Symposium: Philip Jermann - NTRK, RET and other fusion biomarkers testing

• Date :
• 2    
  0

ESMO 2020 Highlights on durability of clinical benefit and biomarkers with AMG510 in NSCLC

• Date :
• 2    
  0

ESMO 2020 Highlights on 1st line durvalumab and tremelimumab for mPDAC: The PA.7 study

• Date :
• 2    
  0

ESMO 2020 Highlights on nivolumab+cabozantinib as 1st line therapy for aRCC: The CheckMate 9ER study

• Date :
• 2    
  0

ESMO 2020 Highlights on pembrolizumab as 1st line therapy for aUC: The KEYNOTE-361 study

• Date :
• 2    
  0

ESMO 2020 Highlights on neoadjuvant mFOLFIRINOX for T3-4 rectal cancer: The PRODIGE 23 study

• Date :
• 2    
  0

ESMO Virtual Congress 2020: anticipations on practice-changing results in gastric cancers

• Date :
• 2    
  0

ESMO Virtual Congress 2020

• Date :
• 2    
  0

OncLive News Network On Location: ESMO 2020 Day 1

• Date :
• 2    
  0

ESMO 2020 Satellite Symposium Philip Jermann talk: Genomic profiling is driving the precision

• Date :
• 1    
  0

ESMO 2020 Gabriela Fernandes talk: Lung cancer diagnostic test needs: perspective from a thoracic

• Date :
• 1    
  0

ESMO 2020 Highlights on blocking PI3K/AKT signalling pathway in mCRPC: The IPATential150 study

• Date :
• 1    
  0

ESMO 2020 Highlights on lenvatinib plus pembrolizumab in advanced solid tumours: LEAP-005

• Date :
• 1    
  0

ESMO 2020 Highlights on neoadjuvant ICI in early TNBC: The IMpassion031 study

• Date :
• 1    
  0

ESMO 2020 Highlights on adjuvant osimertinib for EGFR mutated NSCLC: The ADAURA study

• Date :
• 1    
  0

ESMO 2020 Highlights on 1st line lorlatinib for ALK+ NSCLC: The CROWN Study

• Date :
• 1    
  0

ESMO Congress 2020 Public Policy Sessions

• Date :
• 1    
  0

ESMO Virtual Meeting 2020: anticipations on promising studies in lung cancer

• Date :
• 1    
  0

ESMO W4O Roundtable: Has the COVID-19 pandemic exacerbated gender inequalities?

• Date :
• 0    
  0

ESMO 2020 Highlights on alpelisib plus fulvestrant for HR+/HER2– ABC: The SOLAR-1 study

• Date :
• 0    
  0

ESMO 2020 Highlights on sacituzumab govitecan in metastatic TNBC: The ASCENT study

• Date :
• 0    
  0

ESMO 2020 Highlights on pembrolizumab in LA-HNSCC: The GORTEC 2015-01 “PembroRad” study

• Date :
• 0    
  0

ESMO Virtual Congress 2020: Welcoming the oncology community

• Date :
• 0    
  0

John Haanen on new data presented at ESMO Virtual Congress 2020

• Date :
• 0    
  0

John Haanen tells you why you can't miss ESMO Virtual Congress 2020

• Date :
• 0    
  0

John Haanen on COVID-19 and cancer research?

• Date :
• 0    
  0

John Haanen on how ESMO Virtual Congress 2020 will be different?

• Date :
• 0    
  0

ESMO Vision 2020: Integrated Cancer Care

• Date :
• 0    
  0

ESMO Academy 2020 Virtual Meeting: Welcome to the ESMO Booth!

• Date :
• 0    
  0

OncLive News Network On Location ESMO 2020 Day 2

• Date :
• 0    
  0

4-year results from CheckMate 238: adjuvant nivo vs ipi in resected stage III/IV melanoma

• Date :
• 0    
  0

ADAURA: osimertinib adjuvant therapy in EGFR mutated NSCLC

• Date :
• 0    
  0

Standard-dose vs. high-dose thoracic radiotherapy in limited stage SCLC

• Date :
• 0    
  0

Nurse navigators during COVID-19

• Date :
• 0    
  0

NeoTRIPaPDL1: dynamics of TILs & PD-L1 expression in breast cancer

• Date :
• 0    
  0

Genomic evolution of metastatic tumours under therapeutic pressure

• Date :
• 0    
  0

Thyroid cancer studies at ESMO 2020

• Date :
• 0    
  0

CheckMate 9ER trial: nivo + cab vs sun 1L in advanced RCC

• Date :
• 0    
  0

Clinical trial designs & ESMO-MCBS

• Date :
• 0    
  0

Immunotherapy toxicities and checkpoint inhibitor therapy

• Date :
• 0    
  0

EONS: what can we look forward to?

• Date :
• 0    
  0

QOLIXANE: QoL and efficacy data in 1L pancreatic cancer

• Date :
• 0    
  0

Critical role of eosinophils during response to ICI blockade

• Date :
• 0    
  0

CheckMate 214 trial update

• Date :
• 0    
  0

ORF1ab in SARS-CoV-2

• Date :
• 0    
  0

RCC data at ESMO 2020

• Date :
• 0    
  0

Treating patients with RCC in 2020 and beyond

• Date :
• 0    
  0

Updates in 1L urothelial cancer from ESMO 2020

• Date :
• 0    
  0

Sex and gender differences in medicine

• Date :
• 0    
  0

ESMO economic model for cancer medicines

• Date :
• 0    
  0

Adolescents, young adults and parents of children with cancer: supportive care

• Date :
• 0    
  0

Functional inactivation of E-cadherin drives EMT-less metastasis

• Date :
• 0    
  0

Cancer nursing education and recognition in Europe: A survey by the EONS

• Date :
• 0    
  0

Immunotherapy trial updates in NSCLC from ESMO 2020

• Date :
• 0    
  0

BIONIKK trial update

• Date :
• 0    
  0

The Prolepsis project

• Date :
• 0    
  0

Ovarian cancer Phase III trial updates: IMagyn050/GOG 3015/ENGOT-OV39 and ICON8

• Date :
• 0    
  0

Clinical frailty scale: predictor of prognosis for patients

• Date :
• 0    
  0

Cab + atezo: a new treatment for naïve advanced ccRCC

• Date :
• 0    
  0

BIONIKK: the first trial study in mccRCC

• Date :
• 0    
  0

GU update: ESMO 2020

• Date :
• 0    
  0

PRINCEPS study: atezolizumab for resectable NSCLC

• Date :
• 0    
  0

AMG 160: immunotherapy for Mcrpc

• Date :
• 0    
  0

LungART clinical trial update

• Date :
• 0    
  0

The medium and long-term impacts of COVID-19 on cancer care

• Date :
• 0    
  0

Avelumab maintenance for urothelial cancer

• Date :
• 0    
  0

Sexual function in YA with a brain tumor

• Date :
• 0    
  0

CHRYSALIS trial update in NSCLC

• Date :
• 0    
  0

Ripretinib IPDE following disease progression in GIST

• Date :
• 0    
  0

LEAP-004: initial results

• Date :
• 0    
  0

REACTION clinical trial update

• Date :
• 0    
  0

SECOMBIT: sequencing of targeted agents/immunomodulatory Abs in metastatic BRAFV600-mutated melanoma

• Date :
• 0    
  0

Non-adherence to tamoxifen in CANTO cohort over 3 years

• Date :
• 0    
  0

Nivolumab chemotherapy combination treatment: CheckMate649 and ATTRACTION-4

• Date :
• 0    
  0

Promising new treatments for sarcomas: immunotherapy and fusion targeted compounds

• Date :
• 0    
  0

ISG/OS-2 trial: amending treatment of methotrexate for non metastatic osteosarcoma

• Date :
• 0    
  0

Pembrolizumab plus chemotherapy for esophageal cancer: KEYNOTE-590

• Date :
• 0    
  0

Nivolumab for perioperative esophageal and gastroesophageal cancer: CheckMate-577

• Date :
• 0    
  0

Recent advances in gastrointestinal research: DESTINY-Gastric01 and Spotlight

• Date :
• 0    
  0

Clinical trials in breast cancer: PALLAS, MONARCH-3 and SOLAR-1

• Date :
• 0    
  0

ENGOT-EN3-NSGO/PALEO: Letrozole-palbociclib combination for endometrial cancer

• Date :
• 0    
  0

Clinical trials in gynecological research: Ruby, NORA and IMagyn050

• Date :
• 0    
  0

EPIC-OPC: testing for only p16 can lead to oropharyngeal cancer misclassification

• Date :
• 0    
  0

Update on the NAVIGATOR study

• Date :
• 0    
  0

GIST: an update from ESMO 2020

• Date :
• 0    
  0

CCOS study: disparities in cancer during the COVID-19 pandemic

• Date :
• 0    
  0

ADAURA clinical trial update

• Date :
• 0    
  0

CCC19: assessment of clinical and laboratory prognostic factors

• Date :
• 0    
  0

EONS safety work: Where do we go from here?

• Date :
• 0    
  0

Nursing aspects on the transformation of cancer care during the Covid-19 pandemic

• Date :
• 0    
  0

Update on biomarkers in urothelial cancer presented at ESMO 2020

• Date :
• 0    
  0

PLX8394 in patients with advanced cancer: activity, safety and ctDNA

• Date :
• 0    
  0

CCC19: systemic cancer treatment-related outcomes

• Date :
• 0    
  0

Horizon scanning in GU cancer

• Date :
• 0    
  0

CROWN study: lorlatinib vs crizotinib in 1L NSCLC

• Date :
• 0    
  0

ALTA-1L updates at ESMO 2020: intracranial efficacy and HRQoL

• Date :
• 0    
  0

Ex vivo models of breast cancer

• Date :
• 0    
  0

ACTIVE trial update: EGFRm NSCLC

• Date :
• 0    
  0

LEAP-004: a stepping stone for further research

• Date :
• 0    
  0

ARROW: an update on the registrational study

• Date :
• 0    
  0

Update on the efficacy and safety of the LIBRETTO-531 trial

• Date :
• 0    
  0

Thyroid cancer at ESMO 2020

• Date :
• 0    
  0

Summary of the AToM trial

• Date :
• 0    
  0

Updates in urological cancer presented at ESMO 2020

• Date :
• 0    
  0

KEYNOTE-024 update: pembrolizumab vs platinum-based chemotherapy in NSCLC

• Date :
• 0    
  0

A new mode of collective migration in colorectal cancer dissemination

• Date :
• 0    
  0

ASCENT trial: sacituzumab govitecan for TNBC

• Date :
• 0    
  0

Breast cancer at ESMO 2020: IMpassion131, SOLAR-1, PALLAS and more

• Date :
• 0    
  0

QOL in MONALEESA-2, 3, and 7

• Date :
• 0    
  0

Psychological consequence of COVID-19 on cancer patients

• Date :
• 0    
  0

GINECO TAPAZ clinical trial update

• Date :
• 0    
  0

Genomic alterations in solid tumors according to ESCAT

• Date :
• 0    
  0

Sacituzumab govitecan in metastatic urothelial carcinoma: updates on the Phase II study

• Date :
• 0    
  0

Updates on the DANUBE, KEYNOTE-361 and JAVELIN Studies

• Date :
• 0    
  0

JAVELIN BLADDER 100: 1L urothelial cancer updates

• Date :
• 0    
  0

Impact of biological sex on incidence, pathology and treatment responses to cancer

• Date :
• 0    
  0

FLIPPER trial: an update

• Date :
• 0    
  0

Designing Phase II trials for LMS using PFS as primary endpoint: a STBSG meta-analysis

• Date :
• 0    
  0

PRS-343 in HER2-Positive Solid Tumors: A trial update

• Date :
• 0    
  0

The role of immunotherapy in gastrointestinal cancers: an update from ESMO

• Date :
• 0    
  0

Patient and occupational safety in Europe: A survey by the European Oncology Nursing Society

• Date :
• 0    
  0

ESMO highlights: 705MO study in GU cancer

• Date :
• 0    
  0

Novel intraoral cooling device for cryoprevention of oral mucositis

• Date :
• 0    
  0

Breast cancer at ESMO 2020: CDK4/6 inhibitors and checkpoint inhibitors

• Date :
• 0    
  0

IMvigor130: patient-reported outcomes by the addition of atezolizumab to PBC in mUC

• Date :
• 0    
  0

STIMULI trial update at ESMO 2020

• Date :
• 0    
  0

PRECISION-Panc: platform to enhance biomarker discovery for pancreatic cancer

• Date :
• 0    
  0

Treatment options for mUC following chemo-immunotherapy failure

• Date :
• 0    
  0

Managing comorbidities in lung cancer patients

• Date :
• 0    
  0

Lung ART trial updates from ESMO 2020

• Date :
• 0    
  0

EONS: Young Cancer Nurses study

• Date :
• 0    
  0

Evidence for local treatment of oligometastatic disease

• Date :
• 0    
  0

Pan-cancer analysis of whole genomes

• Date :
• 0    
  0

ADAURA: osimertinib adjuvant therapy on CNS disease recurrence

• Date :
• 0    
  0

Impact of sexual dimorphism in cancer healthcare

• Date :
• 0    
  0

Experience of setting up the PRECISION-Panc platform

• Date :
• 0    
  0

ETOP/IFCT 4-12 STIMULI updates from ESMO 2020

• Date :
• 0    
  0

QuEST1 clinical trial updates

• Date :
• 0    
  0

Congrès ESMO 2026

• Date :
• 799    
  0

Congrès ESMO d'Immuno-Oncologie 2025

• Date :
• 1314    
  0

SABCS 2025 Symposium

• Date :
• 7706    
  0

Congrès ESMO Asie 2025

• Date :
• 948    
  0

17ᵉ Congrès Européen Multidisciplinaire sur le Cancer Urologique - EMUC25

• Date :
• 1409    
  0